These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 16469674)
1. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Korzenik JR; Podolsky DK Clin Gastroenterol Hepatol; 2006 Feb; 4(2):157-9. PubMed ID: 16469674 [No Abstract] [Full Text] [Related]
2. The COX-2 inhibitors--an update. Furberg CD Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896 [No Abstract] [Full Text] [Related]
3. Risks and benefits of celecoxib to prevent recurrent adenomas. Psaty BM; Potter JD N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408 [No Abstract] [Full Text] [Related]
4. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336 [TBL] [Abstract][Full Text] [Related]
5. Drug testing. Massive trial of Celebrex seeks to settle safety concerns. Couzin J Science; 2005 Dec; 310(5756):1890-1. PubMed ID: 16373546 [No Abstract] [Full Text] [Related]
6. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Sakamoto C; Soen S Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022 [TBL] [Abstract][Full Text] [Related]
8. Balancing the risks and benefits of celecoxib. Caldwell B; Beasley R; Weatherall M; Metcalfe S Am J Med; 2007 Jun; 120(6):e17. PubMed ID: 17524734 [No Abstract] [Full Text] [Related]
9. The impact of selective and non-selective non-steroid anti-inflammatory drugs on secondary hemostasis in healthy volunteers. Schjerning O; Larsen TB; Damkier P Thromb Res; 2009 Jun; 124(2):208-12. PubMed ID: 19269020 [TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine and celecoxib may have caused adverse events in an elderly patient. Hori K; Konishi K; Akita R; Tanaka H; Hachisu M Psychiatry Clin Neurosci; 2013 Jul; 67(5):363. PubMed ID: 23859666 [No Abstract] [Full Text] [Related]
11. [Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases]. Guo ZR Yao Xue Xue Bao; 2005 Nov; 40(11):967-9. PubMed ID: 16499077 [No Abstract] [Full Text] [Related]
12. Efficacy and tolerability of celecoxib compared with diclofenac slow release in the treatment of acute ankle sprain in an Asian population. Nadarajah A; Abrahan L; Lau FL; Hwang LJ; Fakir-Bolte C Singapore Med J; 2006 Jun; 47(6):534-42. PubMed ID: 16752024 [TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit? DuBois RN J Clin Oncol; 2006 Jun; 24(18):2691-3. PubMed ID: 16782907 [No Abstract] [Full Text] [Related]
14. Coxibs and cardiovascular risk. Allen MJ; McLean-Veysey P; Fleming I CMAJ; 2005 Oct; 173(8):853. PubMed ID: 16217098 [No Abstract] [Full Text] [Related]
15. An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis. Raynauld JP; Martel-Pelletier J; Beaulieu A; Bessette L; Morin F; Choquette D; Haraoui B; Abram F; Pelletier JP Semin Arthritis Rheum; 2010 Dec; 40(3):185-92. PubMed ID: 20132966 [TBL] [Abstract][Full Text] [Related]
16. [Effective also in Bechterew disease]. MMW Fortschr Med; 2007 Jun; 149(25-26):46-7. PubMed ID: 17713052 [No Abstract] [Full Text] [Related]
17. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs. Spalding WM; Reeves MJ; Whelton A Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969 [TBL] [Abstract][Full Text] [Related]